Recent advances in medical dermatology

Collectively, new developments in the field of medical dermatology will ultimately lead to improved patient care. We review several new findings in the dermatologic literature including the following: new questions regarding the malignant potential of anti‐tumor necrosis factor agents, which are widely used for the treatment of moderate to severe psoriasis as well as psoriatic arthritis; anti‐interleulin‐12, a promising anticytokine for the treatment of psoriasis; diagnostic advances in the detection of latent Mycobacterium tuberculosis; advances in the primary prevention of human papillomavirus and herpes zoster; and new therapeutic options with existing medications for neuropathic pain and pruritus.

[1]  P. Peduzzi,et al.  A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. , 2005, The New England journal of medicine.

[2]  G. von Krogh.  Management of anogenital warts (condylomata acuminata). , 2001, EJD. European journal of dermatology.

[3]  E. Whalen,et al.  Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens , 2005, Pain.

[4]  J. Keane,et al.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. , 2001, The New England journal of medicine.

[5]  P. Andersen,et al.  Comparison of tuberculin skin test and new specific blood test in tuberculosis contacts. , 2004, American journal of respiratory and critical care medicine.

[6]  David W Wareham,et al.  Herpes zoster , 2007, BMJ : British Medical Journal.

[7]  M. Broder,et al.  Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. , 2006, Seminars in arthritis and rheumatism.

[8]  I. Orme,et al.  Mice Lacking Bioactive IL-12 Can Generate Protective, Antigen-Specific Cellular Responses to Mycobacterial Infection Only if the IL-12 p40 Subunit Is Present1 , 2002, The Journal of Immunology.

[9]  A. Vaglio,et al.  Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. , 2005, Journal of nephrology.

[10]  D. Bowsher.  The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: a randomized, double-blind, placebo-controlled trial. , 1997, Journal of pain and symptom management.

[11]  H. Fields,et al.  Endogenous pain control mechanisms: Review and hypothesis , 1978, Annals of neurology.

[12]  Cosette M Wheeler,et al.  Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. , 2005, The Lancet. Oncology.

[13]  I. R. Steinberg,et al.  [Herpes zoster]. , 1950, Prensa medica argentina.

[14]  J. Offord,et al.  The Novel Anticonvulsant Drug, Gabapentin (Neurontin), Binds to the Subunit of a Calcium Channel (*) , 1996, The Journal of Biological Chemistry.

[15]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[16]  S. Whetzel,et al.  Preferential action of gabapentin and pregabalin at P/Q‐type voltage‐sensitive calcium channels: Inhibition of K+‐evoked [3H]‐norepinephrine release from rat neocortical slices , 2002, Synapse.

[17]  A. Rice,et al.  Gabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study , 2001, PAIN.

[18]  T. Yoldas,et al.  Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[19]  I. Coulson,et al.  Brachioradial pruritus: response to treatment with gabapentin , 2004, The British journal of dermatology.

[20]  B. Strober,et al.  The potential of interleukin 12 inhibition in the treatment of psoriasis. , 2005, Journal of drugs in dermatology : JDD.

[21]  C. R. Lankford,et al.  A unique role for IL‐23 in promoting cellular immunity , 2003, Journal of leukocyte biology.

[22]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[23]  R. Whitley,et al.  Clinical practice. Herpes zoster. , 2002, The New England journal of medicine.

[24]  J. Bernhard,et al.  Willan's itch and other causes of pruritus in the elderly , 2005, International journal of dermatology.

[25]  E. Spierings,et al.  Endogenous pain control mechanisms , 1979, Annals of neurology.

[26]  F. X. Bosch,et al.  Chapter 1: Human papillomavirus and cervical cancer--burden and assessment of causality. , 2003, Journal of the National Cancer Institute. Monographs.

[27]  L. Edwards.  New concepts in vulvodynia. , 2003, American Journal of Obstetrics and Gynecology.

[28]  S. Jones,et al.  Sensitivity of human gamma interferon assay and tuberculin skin testing for detecting infection with Mycobacterium tuberculosis in patients with culture positive tuberculosis. , 2005, Tuberculosis.

[29]  A. Fietta,et al.  Comparison of a whole-blood interferon-gamma assay and tuberculin skin testing in patients with active tuberculosis and individuals at high or low risk of Mycobacterium tuberculosis infection. , 2003, American journal of infection control.

[30]  P. Yesudian,et al.  Efficacy of gabapentin in the management of pruritus of unknown origin. , 2005, Archives of dermatology.

[31]  J. Mendham.  Gabapentin for the treatment of itching produced by burns and wound healing in children: a pilot study. , 2004, Burns : journal of the International Society for Burn Injuries.

[32]  B. Metchock,et al.  Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[33]  A. A. al Mazrou,et al.  Booster Effect of Two-Step Tuberculin Skin Testing Among Hospital Employees From Areas With a High Prevalence of Tuberculosis , 2004, Infection Control & Hospital Epidemiology.

[34]  Pregabalin: new drug. Very similar to gabapentin. , 2005, Prescrire international.

[35]  L. Fabbri,et al.  Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. , 2005, American journal of respiratory and critical care medicine.

[36]  R Menzies,et al.  The Booster Effect in Two-Step Tuberculin Testing among Young Adults in Montreal , 1994, Annals of Internal Medicine.

[37]  R. Long,et al.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. , 2003, The Lancet. Infectious diseases.

[38]  F. Brombacher,et al.  A Protective and Agonistic Function of IL-12p40 in Mycobacterial Infection1 , 2001, The Journal of Immunology.

[39]  R. Schmidt,et al.  Active “itch fibers” in chronic pruritus , 2003, Neurology.

[40]  A. Mazrou.  Booster effect of two-step tuberculin skin testing among hospital employees from areas with a high prevalence of tuberculosis. , 2004 .

[41]  J. Yim,et al.  Discrepancy between the tuberculin skin test and the whole-blood interferon gamma assay for the diagnosis of latent tuberculosis infection in an intermediate tuberculosis-burden country. , 2005, JAMA.